Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 7/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.43 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL286882 | 1.00 | HIF1A (0.56) | HIF1ATRAP1CHRNA7ALDH1A1CYP1A2 | |
| Bromide SCHEMBL2446607 | 1.00 | HIF1A (0.56) | HIF1ATRAP1CHRNA7ALDH1A1CYP1A2 | |
| Bromide SCHEMBL678415 | 1.00 | HIF1A (0.56) | HIF1ATRAP1CHRNA7ALDH1A1CYP1A2 | |
| Bromide SCHEMBL1866839 | 1.00 | HIF1A (0.56) | HIF1ATRAP1CHRNA7ALDH1A1CYP1A2 | |
| Bromide SCHEMBL7759526 | 1.00 | HIF1A (0.56) | HIF1ATRAP1CHRNA7ALDH1A1CYP1A2 | |
| Bromide SCHEMBL635580 | 1.00 | HIF1A (0.56) | HIF1ATRAP1CHRNA7ALDH1A1CYP1A2 | |
| Bromide SCHEMBL8775234 | 1.00 | HIF1A (0.56) | HIF1ATRAP1CHRNA7ALDH1A1CYP1A2 | |
| Bromide SCHEMBL164301 | 1.00 | HIF1A (0.56) | HIF1ATRAP1CHRNA7ALDH1A1CYP1A2 | |
| Bromide SCHEMBL2979400 | 1.00 | HIF1A (0.56) | HIF1ATRAP1CHRNA7ALDH1A1CYP1A2 | |
| Bromide SCHEMBL1963378 | 1.00 | HIF1A (0.56) | HIF1ATRAP1CHRNA7ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 492 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713317-A1 | A PROCESS FOR PURIFICATION OF ETHOFUMESATE | Adama Agan Ltd. (IL) | 2026-03-25 | — | — | EP | claimed |
| EP-3955935-B1 | ALKYL-TRIPHENYLPHOSPHONIUM (A-TPP) COMPOUNDS IN COMBINATION THERAPY WITH A GLYCOLYSIS INHIBITOR COMPOUND OR AN OXPHOS INHIBITOR COMPOUND FOR MITOCHONDRIA TARGETING AND FOR USE IN ANTI-CANCER TREATMENTS | LUNELLA BIOTECH INC (CA) | 2026-03-18 | — | — | EP | claimed |
| US-20260022012-A1 | METHOD FOR CATALYTICALLY DRY REFORMING METHANE | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2026-01-22 | — | — | US | claimed |
| US-20250281910-A1 | FIBROUS SILICA LANTHANUM OXIDE-BASED CATALYST FOR DRY REFORMING OF METHANE AND METHODS OF PREPARATION THEREOF | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2025-09-11 | — | — | US | claimed |
| US-12344784-B2 | Stabilized perovskite quantum dot material | QUANTUM ADVANCED SOLUTIONS LIMITED (GB) | 2025-07-01 | — | — | US | claimed |
| US-12274830-B2 | Nitric oxide inhalation therapy for infants with bronchiolitis | BEYOND AIR LTD (IL) | 2025-04-15 | — | — | US | claimed |
| US-12215025-B1 | Fibrous silica zinc oxide-supported nickel catalyst for dry reforming of methane and methods of preparation thereof | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2025-02-04 | — | — | US | claimed |
| CN-115888674-B | Uranium adsorption material, preparation method and application thereof | 核工业北京化工冶金研究院 | 2024-12-20 | — | — | CN | claimed |
| WO-2024236570-A1 | A PROCESS FOR PURIFICATION OF ETHOFUMESATE | ADAMA AGAN LTD. (IL) | 2024-11-21 | — | — | WO | claimed |
| US-20240173512-A1 | METHODS FOR POTENTIATING ANTIMICROBIAL AGENTS | STREETERVILLE CAPITAL, LLC | 2024-05-30 | — | — | US | claimed |
| US-6086661-A | (A)IMIDAZOLINIUM QUATERNARY SALT, (B) PHOSPHONIUM QUATERNARY SALT, OR (C) AN AMMONIUM QUATERNARY SALT; A PAPER-CURL REDUCING COMPOUND; DYE; STABILIZERS, BIOCIDE, WATER SOLUBLE SALT | XEROX CORPORATION (US) | 2000-07-11 | — | — | US | claimed |
| US-5908723-A | Recording sheets | XEROX CORPORATION (US) | 1999-06-01 | — | — | US | claimed |
| US-5846637-A | Coated xerographic photographic paper | XEROX CORPORATION (US) | 1998-12-08 | — | — | US | claimed |
| EP-0877298-A2 | Coated xerographic photographic paper | Xerox Corporation (US) | 1998-11-11 | — | — | EP | claimed |
| EP-0346655-B1 | AN IMPROVED METHOD FOR PREPARING POLYMER SURFACES FOR SUBSEQUENT PLATING THEREON, AND IMPROVED METAL-PLATED PLASTIC ARTICLES MADE THEREFROM | GENERAL ELECTRIC COMPANY (US) | 1993-08-18 | — | — | EP | claimed |
| EP-0346655-A1 | An improved method for preparing polymer surfaces for subsequent plating thereon, and improved metal-plated plastic articles made therefrom | GENERAL ELECTRIC COMPANY (US) | 1989-12-20 | — | — | EP | claimed |
| US-4873136-A | MILD ETCHING; REMOVAL OF RESIDUAL FILM WITH CATIONIC SURFACTANT | GENERAL ELECTRIC COMPANY (US) | 1989-10-10 | — | — | US | claimed |
| EP-0248597-A2 | Phospholipase A2 inhibitors and methods of synthesis | ORTHO PHARMACEUTICAL CORPORATION (US) | 1987-12-09 | — | — | EP | claimed |
| US-4451679-A | RUTHENIUM COMPOUNDS, PHOSPHONIUM OR QUATERNARY AMMONIUM COMPOUNDS | TEXACO INC. (US) | 1984-05-29 | — | — | US | claimed |
| US-3997705-A | Method of coagulating a fluoro-elastomer from an aqueous dispersion thereof | DYNAMIT NOBEL AKTIENGESELLSCHAFT (DT) | 1976-12-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022012-A1 | METHOD FOR CATALYTICALLY DRY REFORMING METHANE | RNF4, SOD1, HRH4 | HIF1A 2283/4885TRAP1 2202/4885CHRNA7 3420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.